Podcast: First drug-eluting contact lens approved in Japan

Acuvue Theravision with Ketotifen from Johnson & Johnson Vision is the first entry into an anticipated category of drug-eluting contact lenses.

Acuvue Theravision with Ketotifen from Johnson & Johnson Vision is the first entry into an anticipated category of drug-eluting contact lenses. This lens was recently approved in Japan for vision correction and allergy symptom relief. Brian Pall, OD, MS, FAAO, director of clinical science at Johnson & Johnson Vision Care, discusses the lens and its technology.

Click here to read this interview's transcript

Click here to watch this interview's video

Related Videos
 Valerie M. Kattouf, OD, associate professor of optometry and chief of the Dr. Robert and Lena Lewenson Center for Pediatric and Binocular Vision, Illinois College of Optometry, speaks with Optometry Times®' Alex Delaney-Gesing on key highlights and takeaways from her 2022 Vision Expo West presentation titled "Myopia Control."
Ashley Tucker, OD, FAAO, FSLS, Dipl ABO, shares highlights from her discussion titled, "Myopia management: past, present, and future," presented during this year's 115th annual SCOPA meeting.
© 2023 MJH Life Sciences

All rights reserved.